Antiamoebic Properties of Laboratory and Clinically Used Drugs against Naegleria fowleri and Balamuthia mandrillaris

Naegleria fowleri and Balamuthia mandrillaris are pathogenic free-living amoebae that infect the central nervous system with over 95% mortality rates. Although several compounds have shown promise in vitro but associated side effects and/or prolonged approval processes for clinical applications have led to limited success. To overcome this, drug repurposing of marketed compounds with known mechanism of action is considered a viable approach that has potential to expedite discovery and application of anti-amoebic compounds. In fact, many of the drugs currently employed in the treatment of N. fowleri and B. mandrillaris, such as amphotericin B, fluconazole, rifampin and miltefosine, are repurposed drugs. Here, we evaluated a range of clinical and laboratory compounds including metformin, quinclorac, indaziflam, inositol, nateglinide, 2,6-DNBT, trans-cinnamic acid, terbuthylazine, acarbose, glimepiride, vildagliptin, cellulase, thaxtomin A, repaglinide and dimethyl peptidase (IV) inhibitor against N. fowleri and B. mandrillaris. Anti-amoebic assays revealed that indaziflam, nateglinide, 2,6-DNBT, terbuthylazine, acarbose and glimepiride exhibited potent amoebicidal properties against both N. fowleri and B. mandrillaris. Notably, all compounds tested showed minimal human (HaCaT) cell cytotoxicity as determined by lactate dehydrogenase release. Prospective research using animal models is warranted to determine the potential of these repurposed compounds, as well as the need for investigating the intranasal route of delivery to treat these devastating infections.

[1]  R. Siddiqui,et al.  Potential Application of Vaporized Drugs via Nasal Inhalers to Prevent Mortality and Central Nervous System Damage Caused by Primary Amoebic Meningoencephalitis Due to Naegleria fowleri. , 2021, ACS pharmacology & translational science.

[2]  A. Debnath Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads , 2021, Expert review of anti-infective therapy.

[3]  Ayaz Anwar,et al.  Metformin-coated silver nanoparticles exhibit anti-acanthamoebic activities against both trophozoite and cyst stages. , 2020, Experimental parasitology.

[4]  R. Siddiqui,et al.  Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19 , 2020, ACS chemical neuroscience.

[5]  Ayaz Anwar,et al.  Gold-Conjugated Curcumin as a Novel Therapeutic Agent against Brain-Eating Amoebae , 2020, ACS omega.

[6]  D. Kyle,et al.  Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae , 2020, bioRxiv.

[7]  Ayaz Anwar,et al.  Repurposing of drugs is a viable approach to develop therapeutic strategies against central nervous system-related pathogenic amoebae. , 2020, ACS chemical neuroscience.

[8]  S. Gupta,et al.  Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology , 2020, Pediatric blood & cancer.

[9]  J. Lorenzo-Morales,et al.  Is Naegleria fowleri an Emerging Parasite? , 2019, Trends in parasitology.

[10]  W. Sullivan,et al.  Repositioning of guanabenz in conjugation with gold and silver nanoparticles against pathogenic amoebae Acanthamoeba castellanii and Naegleria fowleri. , 2019, ACS infectious diseases.

[11]  K. Rajendran,et al.  trans-Cinnamic Acid Conjugated Gold Nanoparticles as Potent Therapeutics against Brain-Eating Amoeba Naegleria fowleri. , 2019, ACS chemical neuroscience.

[12]  R. Siddiqui,et al.  Naegleria fowleri: diagnosis, treatment options and pathogenesis , 2019, Expert Opinion on Orphan Drugs.

[13]  Ayaz Anwar,et al.  Silver Nanoparticle Conjugation-Enhanced Antibacterial Efficacy of Clinically Approved Drugs Cephradine and Vildagliptin , 2018, Antibiotics.

[14]  J. Derisi,et al.  Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen Balamuthia mandrillaris , 2018, mBio.

[15]  M. R. Shah,et al.  Cytotoxic effects of Benzodioxane, Naphthalene diimide, Porphyrin and Acetamol derivatives on HeLa cells , 2018, SAGE open medicine.

[16]  K. Rajendran,et al.  Brain-Eating Amoebae: Silver Nanoparticle Conjugation Enhanced Efficacy of Anti-Amoebic Drugs against Naegleria fowleri. , 2017, ACS chemical neuroscience.

[17]  Eric L. Patterson,et al.  Indaziflam: a new cellulose-biosynthesis-inhibiting herbicide provides long-term control of invasive winter annual grasses. , 2017, Pest management science.

[18]  H. Kalsoom,et al.  Laboratory testing of clinically approved drugs against Balamuthia mandrillaris , 2014, World Journal of Microbiology and Biotechnology.

[19]  J. Perfect,et al.  Brain Inositol Is a Novel Stimulator for Promoting Cryptococcus Penetration of the Blood-Brain Barrier , 2013, PLoS pathogens.

[20]  G. Visvesvara Infections with free-living amebae. , 2013, Handbook of clinical neurology.

[21]  A. Encina,et al.  Cellulose Biosynthesis Inhibitors: Comparative Effect on Bean Cell Cultures , 2012, International journal of molecular sciences.

[22]  T. Heggie Swimming with death: Naegleria fowleri infections in recreational waters. , 2010, Travel medicine and infectious disease.

[23]  R. Siddiqui,et al.  Balamuthia mandrillaris: Staining Properties of Cysts and Trophozoites and the Effect of 2,6‐Dichlorobenzonitrile and Calcofluor White on Encystment , 2009, The Journal of eukaryotic microbiology.

[24]  R. Siddiqui,et al.  Balamuthia amoebic encephalitis: an emerging disease with fatal consequences. , 2008, Microbial pathogenesis.

[25]  F. Schuster,et al.  Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. , 2007, FEMS immunology and medical microbiology.

[26]  F. Schuster,et al.  Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. , 2004, International journal for parasitology.

[27]  W. Scheible,et al.  An Arabidopsis Mutant Resistant to Thaxtomin A, a Cellulose Synthesis Inhibitor from Streptomyces Species Online version contains Web-only data. Article, publication date, and citation information can be found at www.plantcell.org/cgi/doi/10.1105/tpc.013342. , 2003, The Plant Cell Online.

[28]  C. J. Halas Nateglinide. , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  I. Sahid,et al.  Effects of Thiram and Terbuthylazine on Cellulose Decomposition in Two Soils , 1993, Bulletin of environmental contamination and toxicology.